Last updated: September 8, 2026
Adlyxin, the U.S. brand for lixisenatide, has moved from a differentiated diabetes launch product to a commercially marginal and discontinued U.S. therapy. Sanofi launched Adlyxin in 2016 after FDA approval for adults with type 2 diabetes. The product faced weak positioning against longer-acting GLP-1 receptor agonists, modest clinical differentiation, daily injection requirements, and escalating competition from dulaglutide, semaglutide, and tirzepatide.
Sanofi does not report standalone Adlyxin revenue in its public financial statements. The product was not a material contributor to company sales, and its U.S. commercial discontinuation eliminated meaningful future revenue exposure in that market. Lixisenatide remains relevant mainly through the fixed-ratio combination Soliqua, known as Suliqua outside the United States, and through residual international commercialization of Lyxumia.
What is Adlyxin and how does lixisenatide compete?
Adlyxin is a once-daily injectable GLP-1 receptor agonist containing lixisenatide. FDA approved it on July 28, 2016, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[1]
| Attribute |
Adlyxin |
| Active ingredient |
Lixisenatide |
| Drug class |
GLP-1 receptor agonist |
| U.S. manufacturer |
Sanofi |
| U.S. NDA |
208471 |
| FDA approval |
July 28, 2016 |
| Administration |
Once-daily subcutaneous injection |
| Primary indication |
Type 2 diabetes |
| Cardiovascular-outcomes result |
Noninferior to placebo in ELIXA |
| U.S. commercial status |
Discontinued from commercial distribution |
| Principal combination product |
Insulin glargine/lixisenatide, Soliqua |
Lixisenatide activates the GLP-1 receptor and supports glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and reduces food intake. Its pharmacology is broadly consistent with the class, but the commercial market increasingly rewarded longer duration, greater weight loss, simpler dosing, and demonstrated cardiovascular or renal benefits.
When did Adlyxin lose market momentum?
Adlyxin lost competitive momentum shortly after launch because the GLP-1 market was shifting toward once-weekly products and stronger outcome data.
The principal commercial disadvantages were:
- Once-daily injection versus once-weekly dosing for Trulicity, Ozempic, and later Mounjaro.
- More limited weight-loss positioning than semaglutide and tirzepatide.
- No demonstrated cardiovascular-risk reduction in the ELIXA outcomes trial.
- Strong payer and prescriber preference for higher-volume GLP-1 brands.
- Limited differentiation from other diabetes therapies in a crowded category.
- Lack of a major obesity indication.
The ELIXA trial established that lixisenatide was noninferior to placebo for cardiovascular safety in patients with type 2 diabetes and recent acute coronary syndrome. It did not show a statistically significant cardiovascular benefit.[2] This distinction became commercially important as cardiovascular-risk reduction became a major prescribing factor for GLP-1 drugs.
How does Adlyxin compare with leading GLP-1 drugs?
| Product |
Active ingredient |
Dosing |
Cardiovascular positioning |
Commercial position |
| Adlyxin |
Lixisenatide |
Daily |
Cardiovascular safety noninferiority |
Discontinued U.S. commercial product |
| Trulicity |
Dulaglutide |
Weekly |
Cardiovascular benefit demonstrated |
Major diabetes franchise |
| Ozempic |
Semaglutide |
Weekly |
Cardiovascular benefit demonstrated |
Leading GLP-1 product |
| Rybelsus |
Oral semaglutide |
Daily oral |
Cardiovascular data supported class expansion |
Oral alternative |
| Victoza |
Liraglutide |
Daily |
Cardiovascular benefit demonstrated |
Mature, declining franchise |
| Mounjaro |
Tirzepatide |
Weekly |
Strong glycemic and weight-loss efficacy |
Rapid-growth competitor |
| Soliqua |
Insulin glargine/lixisenatide |
Daily |
Fixed-ratio insulin/GLP-1 product |
Niche combination therapy |
Adlyxin was therefore disadvantaged on both convenience and clinical-commercial messaging. Its strongest remaining rationale was use in patients requiring a daily GLP-1 agonist or a treatment aligned with a fixed-ratio basal-insulin combination.
What is the FDA regulatory status of Adlyxin?
Adlyxin received full FDA approval and was not withdrawn for a safety reason. Sanofi subsequently discontinued U.S. commercial distribution. FDA regulatory discontinuation and commercial discontinuation are distinct events: an approved product can remain in FDA records even after the sponsor stops selling it.
The product label carried standard GLP-1 receptor agonist warnings, including risk of thyroid C-cell tumors based on rodent findings, pancreatitis, hypoglycemia when used with insulin or insulin secretagogues, renal impairment, and hypersensitivity reactions.[3]
The FDA approval history is commercially relevant because Adlyxin’s regulatory status does not create a current growth platform. The product has no approved obesity indication and no approved once-weekly formulation.
What is the Orange Book status of Adlyxin?
Adlyxin was approved under NDA 208471 and was eligible for Orange Book listing as a new chemical drug product. Its commercial value from U.S. exclusivity was limited by the timing of launch and the rapid expansion of competing GLP-1 products.
Adlyxin is a small molecule peptide drug, not a biologic under the biosimilar framework. Any future competition would arise through an abbreviated new drug application or other small-molecule pathway, not through a biosimilar application.
No biosimilar risk exists for Adlyxin. The relevant competitive risks are generic lixisenatide, alternative GLP-1 receptor agonists, insulin/GLP-1 combinations, and newer incretin-based therapies.
What patent protection covered lixisenatide?
Lixisenatide was protected by patent families covering the peptide, pharmaceutical compositions, and therapeutic use. Patent protection was also relevant to Soliqua and Suliqua because the fixed-ratio combination combines lixisenatide with insulin glargine.
The commercial importance of those patents has declined because:
- Adlyxin is no longer a major U.S. revenue product.
- The market has moved toward competing GLP-1 and dual-incretin agents.
- The principal U.S. product opportunity has shifted from standalone lixisenatide to combination therapy.
- Any generic launch would face a smaller market than the originator market available at the time of approval.
A patent challenge could still affect residual international sales or combination-product economics, but it would not recreate Adlyxin’s former U.S. commercial opportunity.
How large was Adlyxin’s financial contribution to Sanofi?
Sanofi did not provide a separate Adlyxin revenue line in its consolidated annual reports. The company reported diabetes sales at the franchise level, with major contributions from Lantus, Toujeo, Soliqua, and other products. Adlyxin’s sales were not disclosed as a material standalone category.[4]
That reporting structure supports three conclusions:
- Adlyxin did not reach a revenue scale that required separate disclosure.
- Revenue attribution cannot be calculated from Sanofi’s public financial statements without proprietary prescription or channel data.
- The product’s financial trajectory was commercially negative even before U.S. discontinuation because its market share was small and its category was expanding around rival products.
Adlyxin financial trajectory
| Period |
Commercial event |
Financial implication |
| 2013 |
Lixisenatide marketed in Europe as Lyxumia |
Initial international revenue opportunity |
| 2016 |
FDA approves Adlyxin in the U.S. |
Entry into the U.S. GLP-1 market |
| 2016 |
Soliqua approved in the U.S. |
Lixisenatide gains a combination-product role |
| 2017-2020 |
Weekly GLP-1 products expand |
Relative competitiveness declines |
| 2020 |
ELIXA data remain safety-focused rather than benefit-focused |
Limited cardiovascular differentiation |
| 2021-2023 |
Semaglutide and tirzepatide reshape the category |
Adlyxin becomes commercially marginal |
| 2023 onward |
U.S. Adlyxin commercial availability ends |
No material standalone U.S. growth path |
Sanofi’s larger diabetes portfolio remained economically important, but Adlyxin did not materially affect the group’s revenue trajectory. The key financial exposure shifted to Soliqua and the broader diabetes franchise rather than standalone lixisenatide.
What licensing deals supported Adlyxin?
Lixisenatide originated from Zealand Pharma’s peptide technology and was developed through a collaboration with Sanofi. The relationship gave Sanofi commercial rights to develop and market lixisenatide and related products, including combination therapies.[5]
The licensing structure matters because Adlyxin’s economics were not limited to Sanofi’s manufacturing and commercial costs. Royalty and collaboration obligations could reduce product-level margin, although Sanofi does not disclose standalone Adlyxin profitability.
The strategic value of the collaboration increased when lixisenatide was incorporated into Soliqua. It declined as standalone GLP-1 demand moved toward products with weekly administration, stronger weight-loss effects, and broader outcomes evidence.
What generic entry risks exist for Adlyxin?
Generic entry risk is structurally lower than it would be for a high-revenue branded drug because U.S. Adlyxin sales have already been discontinued. The main risks are commercial substitution and residual international competition rather than a major U.S. patent cliff.
Potential entry scenarios include:
| Scenario |
Timing logic |
Market effect |
| No meaningful generic entry |
Limited market opportunity |
Existing products continue to dominate |
| Generic lixisenatide enters select markets |
Patent and regulatory requirements satisfied |
Price erosion in residual lixisenatide demand |
| Generic competition targets standalone product only |
Combination patents or formulation issues remain relevant |
Limited impact on Soliqua |
| Combination-product competition develops |
Requires separate regulatory and technical pathway |
Greater potential impact on Soliqua and Suliqua |
A generic lixisenatide product would face manufacturing and formulation requirements associated with a peptide drug. The product is not a conventional small-molecule tablet, so development requires control of peptide identity, purity, aggregation, stability, device compatibility, and injection performance.
What formulation and manufacturing barriers affect lixisenatide?
The main technical barriers involve peptide manufacturing and injectable delivery rather than discovery of a new active ingredient.
Relevant intellectual-property and manufacturing areas include:
- Lixisenatide peptide sequence and analog design.
- Pharmaceutical composition and excipient systems.
- Injectable concentration and stability.
- Prefilled pen or delivery-device compatibility.
- Fixed-ratio coformulation with insulin glargine.
- Control of impurities, aggregates, and degradation products.
- Manufacturing consistency at commercial scale.
Soliqua has a more complex technical profile than standalone Adlyxin because insulin glargine and lixisenatide must remain stable and therapeutically consistent in one delivery system. That complexity can create a higher barrier to direct substitution than standalone lixisenatide, although it does not restore Adlyxin’s lost market position.
What litigation and settlement activity affects Adlyxin?
Adlyxin has not been associated with a major publicly reported U.S. patent-litigation campaign comparable with litigation involving high-revenue GLP-1 products such as Ozempic, Wegovy, Trulicity, or Mounjaro.
No major Paragraph IV litigation has defined the current U.S. commercial outlook for Adlyxin. The absence of high-value litigation is consistent with the product’s limited sales base and discontinued U.S. status.
There is also no material biosimilar litigation pathway because lixisenatide is not regulated as a biologic for purposes of the biosimilar approval system.
How strong is the Adlyxin patent estate?
The patent estate was commercially adequate to support launch but is strategically weak in the current market.
Its effective strength is reduced by:
- Loss of U.S. standalone commercial activity.
- Limited product differentiation.
- Competition from superior-performing incretin therapies.
- Lack of an obesity indication.
- Limited value of enforcing patents against a low-demand product.
- Greater commercial importance of combination-product rights than standalone Adlyxin rights.
The strongest remaining IP value is likely connected to formulations, delivery systems, and fixed-ratio combinations rather than to standalone Adlyxin sales.
What is the outlook for Soliqua and international Lyxumia sales?
Soliqua is the principal remaining commercial vehicle for lixisenatide in Sanofi’s portfolio. It targets patients who require basal insulin but may benefit from GLP-1 receptor agonist therapy in a single daily injection.
Its competitive position remains constrained by newer GLP-1 and dual-incretin agents. Soliqua can retain a niche where:
- Basal insulin is clinically necessary.
- A fixed-ratio product is preferred.
- Daily administration is acceptable.
- Payers favor established insulin-based treatment pathways.
- Weight loss is not the primary treatment objective.
Lyxumia may continue in selected international markets, but international availability does not imply a broad growth trajectory. Pricing, reimbursement, local patent status, and the presence of newer GLP-1 products determine its residual commercial value.
Key Takeaways
- Adlyxin is the U.S. brand for lixisenatide, a once-daily GLP-1 receptor agonist approved in 2016.
- Sanofi does not disclose standalone Adlyxin revenue, indicating that the product was not financially material at the company level.
- The product lost competitiveness against weekly GLP-1 therapies and dual-incretin drugs.
- ELIXA established cardiovascular safety but not cardiovascular benefit.
- Adlyxin has been commercially discontinued in the United States without a major safety withdrawal.
- No biosimilar pathway applies; generic and alternative-GLP-1 competition are the relevant risks.
- Soliqua is more commercially relevant than standalone Adlyxin because it combines lixisenatide with insulin glargine.
- The remaining patent value is concentrated in formulations, delivery systems, and combination products.
- Adlyxin has no credible standalone U.S. growth trajectory.
FAQs
Is Adlyxin still available in the United States?
No. Sanofi discontinued U.S. commercial availability of Adlyxin. The product may remain in FDA regulatory records despite the end of commercial distribution.
Is lixisenatide the same drug as Adlyxin?
Yes. Adlyxin is the U.S. brand name for lixisenatide. Lyxumia is the principal international brand name.
Does Adlyxin have an obesity indication?
No. Adlyxin was approved for glycemic control in adults with type 2 diabetes and does not have an FDA-approved chronic weight-management indication.
Is Soliqua a biosimilar to Adlyxin?
No. Soliqua is a fixed-ratio combination of insulin glargine and lixisenatide. It is a separate pharmaceutical product, not a biosimilar or generic version of Adlyxin.
Which drugs replaced Adlyxin commercially?
The main commercial substitutes are dulaglutide, semaglutide, tirzepatide, liraglutide, and insulin/GLP-1 combination products. Weekly semaglutide, dulaglutide, and tirzepatide established the strongest competitive advantage.
References
- U.S. Food and Drug Administration. (2016). FDA approves Adlyxin to treat type 2 diabetes. https://www.fda.gov
- Pfeffer, M. A., Claggett, B., Diaz, R., et al. (2015). Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New England Journal of Medicine, 373(23), 2247-2257. https://doi.org/10.1056/NEJMoa1509225
- U.S. Food and Drug Administration. (2023). Adlyxin prescribing information. Sanofi. https://www.accessdata.fda.gov
- Sanofi. (2016-2023). Annual reports and universal registration documents. https://www.sanofi.com
- Zealand Pharma. (2013-2023). Annual reports and company disclosures concerning lixisenatide and the Sanofi collaboration. https://www.zealandpharma.com
